A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years. Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy. However, responses are generally of limited duration, and complete responses are rare. Preclinical work suggests that human recombinant interleukin-2 (rIL-2; aldesleukin, Proleukin) enhances rituximab efficacy. Antibody-dependent cellular cytotoxicity (ADCC) is an important mechanism of action of rituximab. rIL-2 induces expansion and activation of Fc receptor (FcR)–bearing cells, thereby enhancing ADCC. Therefore, a large, multicenter phase 2 trial to assess the effects of rIL-2 on rituximab therapy in patients with rituxumab-refractory low-grade NHL was conducted. Experimental Design: The combination of rituximab and rIL-2 was studied in 57 patients with rituximab-refractory low-grade NHL (i.e., patients must have received a single-agent course of rituximab and showed no tumor response, or had a response lasting <6 months). I.V. rituximab was given at 375 mg/m2 (weeks 1-4). S.C. rIL-2 was given thrice a week at 14 MIU (weeks 2-5) and at 10 MIU (weeks 6-9). Results: Rituximab plus rIL-2 combination therapy was safe and generally well tolerated, but responses were low. Fifty-seven patients were enrolled with 54 evaluable for response; however, only five responses (one complete and four partial) were observed. Correlative data indicate that rIL-2 expanded FcR-bearing cells and enhanced ADCC. However, other factors, such as FcγR polymorphisms in patients refractory to single-agent rituxumab and heterogeneous tumor biology, may have influenced the lack of clinical efficacy seen with this combination therapy. Conclusions: rIL-2 expands FcR-bearing cellular subsets in vivo and enhances in vitro ADCC of rituxumab. However, these findings do not directly translate into meaningful clinical benefit for patients with rituxumab-refractory NHL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Self-citationInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Cited by
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Self-citationAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Targeted nanoparticles for cancer therapy
Gu, F. X., Karnik, R., Wang, A. Z., Alexis, F., Levy-Nissenbaum, E., Hong, S., Langer, R. S., & Farokhzad, O. C. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70083-x · Cited by 478
Metadata
- Authors
- Khan, K. D., Emmanouilides, C., Benson, D. M., Hurst, D., Garcia, P., Michelson, G., Milan, S., Ferketich, A. K., Piro, L., Leonard, J. P., Porcu, P., Eisenbeis, C. F., Banks, A. L., Chen, L., Byrd, J. C., & Caligiuri, M. A.
- Venue
- Clinical Cancer Research
- Published
- 2006-12-01
- Volume
- 12
- Issue
- 23
- Pages
- 7046-7053
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2165172574
- Cited by
- 99
- References
- 3
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-06-1571
- The paper
- Khan, K. D., Emmanouilides, C., Benson, D. M., Hurst, D., Garcia, P., Michelson, G., Milan, S., Ferketich, A. K., Piro, L., Leonard, J. P., Porcu, P., Eisenbeis, C. F., Banks, A. L., Chen, L., Byrd, J. C., & Caligiuri, M. A. (2006). A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-06-1571
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.